The Effect of Mirabegron on Bladder Blood Flow in a Rat Model of Bladder Outlet Obstruction
Overview
Authors
Affiliations
Purpose: To evaluate the effects of mirabegron on bladder blood flow in a rat model of bladder outlet obstruction (BOO).
Methods: Adult female Sprague-Dawley rats were divided into three groups based on whether they underwent a sham operation (sham group) or an operation to establish partial BOO (BOO and BOO + mirabegron groups). The BOO + mirabegron group was treated with mirabegron (0.3 mg/kg/h, subcutaneously) for 14 days. Subsequently, we performed continuous cystometry, bladder blood flow measurements with a 2D laser blood flow imager, hematoxylin-eosin staining of the bladder tissue, and malondialdehyde (MDA) measurements in the bladder tissue.
Results: Cystometry revealed significantly higher peak pressure, more residual urine volume, and lower voiding efficiency in the BOO and BOO + mirabegron groups than in the sham group. The BOO + mirabegron group had significantly fewer non-voiding contractions (NVCs) than the BOO group, while the latter had more frequent NVCs than the sham group. The BOO and BOO + mirabegron groups had significantly decreased bladder blood flow than the sham group, whereas the BOO + mirabegron group showed significantly increased bladder blood flow than the BOO group. The bladder tissue in the BOO group contained more hypertrophic detrusor muscle compared to the sham group, while mirabegron treatment suppressed detrusor hypertrophy. The MDA levels were significantly higher in the BOO group than in the BOO + mirabegron and sham groups.
Conclusion: Mirabegron treatment significantly improved BOO-induced bladder dysfunction through the amelioration of bladder blood flow.
Luo H, Zhou H, Chen Y, Sun X, Li Y, Li G J Cell Mol Med. 2024; 28(14):e18545.
PMID: 39031471 PMC: 11258885. DOI: 10.1111/jcmm.18545.
Tarcan T, Choi H, Azadzoi K Int J Mol Sci. 2022; 23(24).
PMID: 36555629 PMC: 9782153. DOI: 10.3390/ijms232415988.
Zhu B, Kang Z, Zhu S, Zhang Y, Lai X, Zhou L Front Cell Dev Biol. 2022; 9:772534.
PMID: 35071227 PMC: 8777291. DOI: 10.3389/fcell.2021.772534.
Sakalis V, Gkotsi A, Charpidou D, Tsafrakidis P, Apostolidis A Cent European J Urol. 2021; 74(3):388-421.
PMID: 34729231 PMC: 8552938. DOI: 10.5173/ceju.2021.132.R1.